Diagnosis and pathophysiology of migraine

References

• Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence andburden of migraine in the united states. Data from the American Migraine Study II. Headache 41,646–657 (2001).
   Google Scholar
• Hu HX, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med. 159(8), 813–818 (1999).
   Google Scholar
• Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. /AIWA 290,2443–2454 (2003).
   Google Scholar
• Graham JR, Wolff HG. Mechanisms of migraine headache and action of ergotamine tartrate. Arch. Neural. Psych. 39, 737–763 (1938).
   Google Scholar
• Goadsby PJ, Lipton, RB, Ferrari MD. Migraine: current understanding and management. N Engl. I Med. 346, 257–270 (2002).
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the currentunderstanding of migraine and how therapy relates to pathophysiology.
   Google Scholar
• Ad Hoc Committee on Classification of Headache. Classification of headache. JA/VIA 179,717–718 (1962).
   Google Scholar
• Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 8\(Suppl. 7), 1–96 (1988).
   Google Scholar
• Smith R, Hasse LA, Ritchey PN, Cassedy AE, Rudawsky DJ. Extent of migraine and migrainous headache NOS in family practice. Cephalalgia 21,291–292 (2001).
   Google Scholar
• Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 38, 87–96 (1998).
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Dahlöf C, Dowson A, Newman L. prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from The Landmark Study. (2004) (In Press).
   Google Scholar
• •Useful data about accuracy of migraine diagnosis in primary care offices worldwide.
   Google Scholar
• Kaniecki RG. Migraine and tension-type headache: an assessment of challenges in diagnosis. Neumlogy58\(Suppl. 6), S15—S20 (2002).
   Google Scholar
• Cady RK, Schreiber CR Sinus headache or migraine? Considerations in making a differential diagnosis. Neurology58\(Suppl. 6), S10—S14 (2002).
   Google Scholar
• Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J, Harrison W A self-administered screener for migraine in primary care. The ID Migraine Tm validation study. Neurology61, 375–382 (2003).
   Google Scholar
• Lipton RB, Stewart WF, Stone AM, Lainez MJ, Sawyer JP. Stratified care vs. step care strategies for migraine. The Disabilty in Strategies of Care (DISC) study, a randomized tria1.161/11A 284,2499–2505 (2000).
   Google Scholar
• Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 41 (9), 854–861 (2001).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Lipton RB, Goadsby PJ. Headache in Clinical Practice. Second Edition. Martin Dunitz, London, UK (2002).
   Google Scholar
• ••Outstanding textbook which thoroughlyreviews the topic of headache.
   Google Scholar
• Barbanti P, Fabbrini G, Pesare M, Vanacore N, Cerbo R. Unilateral cranial autonomic symptoms in migraine. Cephalalgia 22(4), 256–259 (2002).
   PubMed Web of Science ®Google Scholar
• Peroutka SJ. The pharmacology of current antimigraine drugs. Headache 30\(Suppl. 1), 5–11 (1990).
   Google Scholar
• Curran DA, Hintterberger H, Lance JW. Total plasma serotonin, 5- hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain 88, 997–1010 (1965).
   Google Scholar
• Kimball RVV, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology 10,107–111 (1960).
   PubMed Web of Science ®Google Scholar
• Humphrey PPA, Feniuk W Perren MJ. Antimigraine drugs in development: advances in serotonin receptor pharmacology. Headache 30\(Suppl. 1), 12–16 (1990).
   Google Scholar
• Joutel A, Bausser MG, Biousee V. A gene for familial hemiplegic migraine maps to chromosome 19. Nature Genet. 5,40-45 (1993).
   Google Scholar
• May A, Ophoff RA, Terwindt GM etal Familial hemiplegic migraine locus on chromosome 19p13 is involved in the common forms of migraine with and without aura. Hum. Genet. 96,604-608 (1995).
   Google Scholar
• ••Key article in understanding underlyinggenetic/pathophysiologic abnormalities in migraine.
   Google Scholar
• Ophoff RA,Terwindt GM, Vergouwe MN. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNLA4. Cell Tiss. Res. 87,543-552 (1996).
   Google Scholar
• Ramadan NM, Halvorson H, VandeLinde A, Levine SR, Helpen JA, Welch KMA. Low brain magnesium in migraine. Headache 29,416–419 (1989).
   PubMedGoogle Scholar
• Welch KM, D'Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neumlogic Clinics 8 (4), 817–828 (1990).
   PubMed Web of Science ®Google Scholar
• De Fusco M, Marconi R, Silvestri L etal Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump a2 subunit associated with familial hemiplegic migraine type 2*. Natum Genet. 33(2), 192–196 (2003)
   Google Scholar
• Peroutka SJ, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Ncol alleles. Eurology 49, 201–206 (1997).
   Google Scholar
• Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 8(2), 83–91 (1988).
   Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neural 28, 183–187 (1990).
   Google Scholar
• Roon KI, Olesen J, Diener HC et al No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized double-blind, placebo-controlled clinical trials. Ann. Neural 47, 238–241 (2000).
   Google Scholar
• Doods H, Hallermayer G, Wu D eta]. Pharmacologic profile of BIBN-4096B5, the first selective small molecule CGRP antagonist. Br. Phannacol 129,420–423 (2000).
   Google Scholar
• Hoskins KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: a c-fos and electrophysiologic study. Brain 119, 249–256 (1996).
   PubMed Web of Science ®Google Scholar
• Mendell LM. Physiologic properties of unmyelinated fibre projection to the spinal cord. Exp. Neural 16,316–332 (1966).
   PubMed Web of Science ®Google Scholar
• Woolf, CJ. Central sensitization: implications for the pathogenesis of headache. In: Towards Mgmine 2000. Rose FC (Ed.). Elsevier, London, UK, 173–181 (1996).
   Google Scholar
• Burstein R, Cutrer FM, Yarnitsky D. The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123,1703–1709 (2000).
   PubMed Web of Science ®Google Scholar
• Burstein R, Collins B, Bajwa Z, Jukubowski M. Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: clinical and preclinical evidence. Headache 42 (5), 390–391 (2002).
   Google Scholar
• Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann. Neural 55 (1), 27–36(2004).
   PubMed Web of Science ®Google Scholar
• Woolf CJ. Somatic pain: pathogenesis and prevention. Br. Anaesth. 75,169–176 (1995).
   PubMed Web of Science ®Google Scholar
• Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiologic study. Cephalalgia 12, 221–228 (1992).
   PubMed Web of Science ®Google Scholar
• Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of RCBF in classic migraine. Ann. Neural. 9,344–352 (1981).
   Google Scholar
• Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Arch. Neural. 46,331–339 (1941).
   Google Scholar
• Leao AAP. Spreading depression of activity in cerebral cortex. J: Neurophysiol 7, 359–390 (1944).
   Google Scholar
• Woods RP, Iacoboni M, Mazziotta JC. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headaches. N Engl. J Med 331,1689–1692 (1994).
   Google Scholar
• Hadjilchani N, Sanchez Del Rio M, Wu 0 et al Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Bun Nat/Arad Sri. 98(8), 4687–4692 (2001).
   Google Scholar
• Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal afferents in a migraine model. Nature Med. 8(2), 136–142 (2002).
   Google Scholar
• •Important article explaining the dynamics of migraine pathophysiology.
   Google Scholar
• Iadecola C. From CSD to headache: a long and winding road. Nature Med. 8(2), 110–112 (2002).
   Google Scholar
• Weiller C, May A, Limmroth V eta]. Brainstem activation in spontaneous human migraine attacks. Nature Med 1(7), 658–660 (1995).
   PubMed Web of Science ®Google Scholar
• Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache 27,416–420 (1987).
   PubMed Web of Science ®Google Scholar
• Ward TN, Levin M. Headache caused by a spinal cord stimulator in the upper cervical spine. Headache 40,689–691 (2000).
   PubMed Web of Science ®Google Scholar
• Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 41 (7), 629–637 (2001) .
   Google Scholar
• •Important article suggesting possible brain damage/dysfunction in patients with chronic headaches.
   Google Scholar
• Humphrey PP, Bland-Ward PA, Carruthers AM etal Inhibition of trigeminal nociceptive afferents by adenosine Al receptor activation: a novel approach towards the design of new antimigraine compounds. Cephalalgia 21,268–269 (2001).
   Google Scholar
• Olesen J, Diener HC, Husstedt IW et al Calcitonin Gene-related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine. N Engl. j Med 350(11), 1104–1110 (2004)
   Google Scholar
• Silberstein SD, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventative treatment. Headache 40, 445–450 (2000).
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Second Edition. www.i-h-s.org (Accessed April 2004) New 2004 classification of headaches.
   Google Scholar
• www.headachetest.com (Accessed April 2004)
   Google Scholar
• www.headaches.org (Accessed April 2004)
   Google Scholar
• www.achenet.org (Accessed April 2004)
   Google Scholar
• www.aan.com (Accessed April 2004)
   Google Scholar